Items Tagged ‘News’

December 31, 2018

Targeted Radiation with 177Lu-PSMA-617 is Promising Treatment for Advanced Prostate Cancer

By

177Lu-PSMA-617 is a member of a new class of drugs that deliver radiation directly to tumor cells to obliterate them. These targeted radiation treatments consist of a radioactive isotope attached to a molecule that specifically targets tumor cells. In this case, the radioactive isotope is 177-lutetium (177Lu), an unstable form of the element lutetium, which […]

View full entry

Tags: News, Prostate Cancer


December 28, 2018

Immunotherapy Offers New Hope in Triple Negative Breast Cancer

By

Results from the Impassion 130 clinical trial published in the New England Journal of Medicine have demonstrated that immunotherapy can improve survival in breast cancer, especially in anti-programmed cell death ligand 1 (PD-1+) patients.  The results were seen with the PD-L1 drug Tecentriq used in combination with chemotherapy for the treatment of triple negative breast cancer. […]

View full entry

Tags: Breast Cancer, News


December 21, 2018

Herceptin Biosimilar Herzuma Approved for Certain Breast Cancer Indications

By

The FDA has approved Celltrion and Teva’s Herzuma (trastuzumab-pkrb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer. Herzuma is the second oncology biosimilar approval in the United States in the past month. Specifically, Herzuma is approved to treat: Adjuvant breast cancer of HER2 overexpressing node positive or node negative (ER/PR negative […]

View full entry

Tags: Breast Cancer, News


December 19, 2018

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer

By

SAN ANTONIO — Patients with triple-negative breast cancer who delayed starting adjuvant chemotherapy for more than 30 days after surgery were at significantly higher risk for disease recurrence and death compared with those who started the treatment in the first 30 days after surgery, according to a retrospective study presented at the 2018 San Antonio Breast […]

View full entry

Tags: Breast Cancer, News


December 12, 2018

Trastuzumab emtansine Improves Treatment of Early Stage HER 2-positive Breast Cancer

By

Adjuvant trastuzumab emtansine showed improved disease-free survival compared with trastuzumab in HER2-positive early breast cancer. Patients with HER 2-positive early stage breast cancer with residual disease who received adjuvant trastuzumab emtansine (T-DM1) had improved disease-free survival compared to patients who received adjuvant trastuzumab, according to the results from the phase 3 KATHERINE trial. Previously reported […]

View full entry

Tags: Breast Cancer, News


December 11, 2018

Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors

By

Treatment with oxybutynin helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a trial presented at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4–8. Hot flashes, a common symptom of menopause, can be more severe in breast […]

View full entry

Tags: Breast Cancer, News


December 10, 2018

Choice of surgery may affect quality of life for young breast cancer survivors

By

Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research by Dana-Farber/Brigham and Women’s Cancer Center. The findings, presented at the San Antonio Breast Cancer Symposium, underscore the importance of counseling patients about the […]

View full entry

Tags: Breast Cancer, News


November 29, 2018

Gilteritinib Approved for Advanced Acute Myeloid Leukemia (AML) with a FLT3 Mutation

By

The U.S. Food and Drug Administration approved Xospata (gilteritinib) for treatment of adult patients who have recurrent or refractory acute myeloid leukemia (AML) with a FLT3 mutation. About Xospata Xospata has demonstrated inhibitory activity against FLT3 internal tandem duplication (ITD) as well as FLT3 tyrosine kinase domain (TKD), two common types of FLT3 mutations that […]

View full entry

Tags: Acute Myeloid Leukemia, Leukemia, News


November 28, 2018

Tissue “Agnostic” Genomic Based Treatment With Vitrakvi and Keytruda – A Paradigm Shift in Cancer Treatment

By

The US Food and Drug Administration (FDA) on Monday approved a new precision cancer medicine Vitrakvi (larotrectinib) for the treatment of adult and pediatric solid tumors that have a targetable biomarker known as a neurotrophic receptor tyrosine kinase (NTRK) gene fusion. This represents a major paradigm shift in how doctors and their patients will need […]

View full entry

Tags: General, News


November 26, 2018

FDA Approves Venclexta Combination for AML in Adults

By

The Food and Drug Administration granted accelerated approval to Venclexta (venetoclax) in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Approval was based on two open-label […]

View full entry

Tags: Acute Myeloid Leukemia, Leukemia, News


July 23, 2018

Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation

By

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test. Data leading to the FDA approval was from a trial that included […]

View full entry

Tags: Acute Myeloid Leukemia, IGH1 Mutation, Leukemia, News, refractory, relapsed, Tibsovo, treatment


July 23, 2018

FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer

By

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. The FDA also approved Kisqali in combination with fulvestrant for the […]

View full entry

Tags: Breast Cancer, News


July 19, 2018

Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN

By

Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). About Head and Neck Cancer Head and neck cancers include a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and […]

View full entry

Tags: EGFR, Head and Neck Cancer, News, Nimotuzumab, treatment


July 17, 2018

FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer

By

On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population to include patients with both non-metastatic CRPC (NM-CRPC) and metastatic CRPC. Xtandi was previously approved for the treatment of patients with metastatic CRPC. About Prostate Cancer Prostate cancer is […]

View full entry

Tags: News, Prostate Cancer


July 12, 2018

Cyramza Improves Survival in Poor-Prognosis Liver Cancer

By

Andrew X. Zhu, MD, PhD, director of Liver Cancer Research at Massachusetts General Hospital presented new data at the 2018 World Congress on Gastrointestinal Cancer (WCGC) demonstrating that Cyramza (ramucirumab) significantly improves survival in a subset of patients with hepatocellular carcinoma (HCC) who have high levels of the plasma protein α-fetoprotein (AFP), which is associated […]

View full entry

Tags: cyramza, hepatocellular cancer treatment, Liver Cancer, News